PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence
This study, called PACHA-02, is for people who have had surgery to remove bowel cancer that has spread to their liver. Even after surgery, there's a risk the cancer could return. This trial is testing whether giving extra chemotherapy directly into the liver's blood supply, in addition to standard chemotherapy given by drip into a vein, can reduce this risk. The main goal is to see if this special chemotherapy can help people stay cancer-free for longer. Researchers will also look at how long people live, if the cancer comes back in the liver, and how safe the treatment is. This is a Phase III study, which means it's a big study to confirm if the new treatment works better than current approaches.
At a glance
What is this study about?
This study is designed for adults who have had surgery to remove bowel cancer that has spread to their liver. When cancer spreads from one part of the body to another, it's called 'metastasis'. In this case, the cancer started in the bowel and then developed in the liver. Even after successful surgery to remove these liver tumours, there's always a chance the cancer could come back.
The trial wants to find out if giving a specific type of chemotherapy directly into the liver's main artery (a blood vessel supplying the liver), called hepatic arterial chemotherapy, makes a difference. This is added to standard chemotherapy given into a vein. The idea is that delivering chemotherapy directly to the liver might be more effective at killing any remaining cancer cells there, reducing the risk of the cancer returning.
The main thing doctors will be looking for is how long patients stay cancer-free after their treatment, which they call 'progression-free survival'. They'll also be tracking other important things like how long people live overall, whether the cancer comes back specifically in the liver, and if the treatment causes any side effects. Researchers will also carefully monitor the quality of life for participants during the study to understand the overall impact of the treatments.
Key takeaways
- This study is testing a new way to prevent bowel cancer from returning in the liver after surgery.
- It involves giving extra chemotherapy directly to the liver's blood supply.
- The main goal is to see if this treatment helps people stay cancer-free for longer.
- The study also looks at how long people live and the treatment's side effects and impact on quality of life.
- Participation will involve regular hospital visits for treatments and check-ups.
- You can discuss with your doctor if this study is suitable for you.
Who may be eligible?
To be considered for this study, you must be an adult, aged 18 or over. This study is specifically for people who have had surgery to completely or almost completely remove bowel cancer that has spread to their liver. Your doctors would have confirmed that all or most of the visible cancer was removed during your operation.
Both men and women can take part in this research. The study team will review your medical history and test results carefully to make sure this trial is the right fit for you. There will be specific medical criteria you need to meet, which your doctor will discuss with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you had bowel cancer that spread to your liver?
- Has your liver cancer been removed by surgery (completely or almost completely)?
- Are you generally well enough to receive chemotherapy treatments?
- Are you able to attend regular hospital appointments?
What does participation involve?
If you join this study, you will be randomly assigned to receive either the standard chemotherapy treatment or the standard chemotherapy plus the additional chemotherapy delivered directly to your liver. This 'random assignment' is like flipping a coin to ensure a fair comparison between the two groups. You will receive a combination of chemotherapy drugs, which may include fluorouracil, folinic acid, oxaliplatin, and irinotecan.
Participation will involve regular hospital visits for your chemotherapy treatments and check-ups. Doctors will monitor you closely using blood tests, scans, and other assessments to track your progress, check for any side effects, and see if the cancer has returned. The total duration of your active treatment will vary depending on your assigned group and how you respond, but follow-up will continue for a defined period to monitor your long-term health and the cancer's status. The care team will explain the full schedule and commitment if you are considering joining.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What kind of cancer is this study for?
This study is for people who have had bowel cancer that spread to their liver, and then had an operation to remove it.
What are doctors trying to find out?
They want to see if giving extra chemotherapy directly into the liver helps stop the cancer from coming back after surgery, and if it helps people live longer.
What does 'Phase III' mean?
It means this is a large study to confirm if a new treatment is better than existing ones, and to get enough information for it to potentially become a standard treatment.
Will I definitely get the new treatment?
No, you will be randomly assigned to either receive the standard treatment or the standard treatment plus the new liver chemotherapy.
How will my health be monitored?
You'll have regular appointments, blood tests, and scans to check your health and how the treatment is working.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.